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Abstract: 
We are reporting the discovery of small molecule inhibitors for vascular endothelial growth factor receptor type 2 (VEGFR-2) 
extracellular domain. The VEGFR-2 extracellular domain is responsible for the homo-dimerization process, which has been recently 
reported as a main step in VEGFR signal transduction cascade. This cascade is essential for the vascularization and survival of most 
types of cancers. Two main design strategies were used; Molecular docking-based Virtual Screening and Fragment Based Design 
(FBD). A virtual library of drug like compounds was screened using a cascade of docking techniques in order to discover an 
inhibitor that binds to this new binding site. Rapid docking methodology was used first to filter the large number of compounds 
followed by more accurate and slow ones. Fragment based molecular design was adopted afterwards due to unsatisfactory results 
of screening process. Screening and design process resulted in a group of inhibitors with superior binding energies exceeding that 
of the natural substrate. Molecular dynamics simulation was used to test the stability of binding of these inhibitors and finally the 
drug ability of these compounds was assisted using Lipinski rule of five. By this way the designed compounds have shown to 
possess high pharmacologic potential as novel anticancer agents.  
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Background: 
Neo-angiogenesis has a crucial role in the progression and 
survival of most types of cancer beside some other proliferative 
diseases  [1]. Vascular endothelial growth factors (VEGFs) are 
the most important angiogenesis regulators [2]. Recognition of 
the crucial role of VEGF pathway in the regulation of 
angiogenesis has led to the development of VEGF-targeted 
therapy for the development of selective and safe anticancer 
agents. Several strategies were taken in consideration in 
targeting the VEGF signaling pathway. Neutralization of the 
VEGF or VEGFR using antibodies was investigated and has 
been reported for treatment of metastatic colorectal cancer [3], 
non-small cell lung cancer [4] and metastatic breast cancer [5]. 
Targeting VEGFR using small molecule inhibitors was another 
strategy as well. The small molecule VEGFR-2 kinase inhibitors 
sorafenib [6] and sunitinib [7] have been approved by the FDA 
for the treatment of advanced renal cell carcinoma [8]. A 
number of other small-molecule tyrosine kinase inhibitors are 
currently under investigation in Phase III clinical trials.   
Another approach includes the use of Peptoid ligands for the 
extracellular domain of VEGFR5 [9]. VEGFR-2 is considered to 
be the major receptor responsible for mediating physiological 
and pathological effects of VEGF- A on endothelial cells [10]. 
Although VEGFR-1 has a tenfold higher binding affinity to 
VEGF, it exerts less activation of intracellular signaling 
intermediates than VEGFR2 and consequently it can act as a 
negative regulator of angiogenesis by binding VEGF and 
preventing its binding to VEGFR-2 [2]. After the Determination 
of the crystal structure of the most membrane proximal domain 
[11], it was revealed that homotypic contacts between them are BIOINFORMATION  open access 
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essential for ligand-induced receptor activation and cell 
signaling. These  contact s we re shown to b e m ediate d by salt  
bridges and van der Waals contacts formed between Arg726 of 
one protomer and Asp731 of the other protomer which was 
proved by the fact that ligand-induced auto-phosphorylation 
and cell signaling via VEGFR1 or VEGFR2 harboring mutations 
in critical residues (Arg726 or Asp731) are impaired. The newly 
discovered homotypic contact region of VEGFR2 provides a 
novel target for pharmacological intervention of pathological 
activation of VEGFR2 which is essential for cancer 
development. In this study, we have used the newly discovered 
crystal structure of the extracellular domain of the VEGFR for 
the purpose of developing a small molecule anti-angiogenic 
drug candidate as anticancer agent through inhibition of the 
VEGFR dimerization process. For this purpose we have used 
molecular docking techniques for virtual high throughput 
screen (v-HTS) for an inhibitor of this process [12]. 
Additionally, fragment based design (FBD) was also employed 
in contrast as an alternate strategy in developing molecular 
designs of relatively higher binding affinities [13].  
 
Materials and Methodology: 
The 3D X-ray crystal structure of monomeric and homodimeric 
forms of membrane-proximal Ig-like domain of the ectodomain 
(D7) of VEGFR-2 [PDB ID: 3KVQ] was exploited as target for 
vitrual High-throughput screening (v-HTS) and fragment-based 
design (FBD). Both the proteins were prepared, undergone rigid 
and flexible docking, energetically probed, and subjected to 
molecular dynamics (MD) simulations. All computational 
analysis was carried out using Discovery Studio (DS) 2.5 
(Accelrys Software Inc., San Diego; http://www.accelrys.com). 
The hardware used was the workstation cluster of 
pharmaceutical chemistry department, at Ain Shams 
University, Faculty of Pharmacy. 
 
Receptor/Ligands preparation: 
The target domain monomeric form as well as the 
homodimerized complex (biological assembly coordinates file) 
were obtained, structure cleaned, the hydrogen atoms were 
added, typing was carried out by all-atom CHARMm forcefield 
(version 35b1) (Momany-Rone partial charges method) [14] and 
followed by Smart Minimizer algorithm – an algorithm that 
performs 1000 steps of Steepest Descent with a root mean 
square (RMS) gradient tolerance of 3, followed by Conjugate 
Gradient minimization – until the RMS gradient for potential 
energy was less than 0.05 kcal ⁄mol⁄Å. Using the 'Binding Site' 
tools available in DS 2.5 the binding site was defined to be the 
homotypic contact region inscribed inside a sphere of 13.5 Å 
radius. Ligands for virtual screening were obtained from Zinc 
database (http://zinc.docking.org) from commercially available 
lead-like compounds, filtered and then prepared using the 
'Prepare Ligands' protocol in order to standardize charges, 
enumerate ionization states and generate tautomers at 
physiological pH range (the eventual count of the library 
reached around 110,000 molecules). The ligands were typed 
similarly by CHARMm for partial charges set up. The last two 
steps were additionally carried out to the 'De Novo' designed 
ligands prior to their flexible docking. 
 
High-throughput docking: 
Rigid molecular docking is the computational method used to 
predict the binding of the ligand to the receptor binding site by 
varying position and conformation of the ligand keeping the 
receptor fixed. Initially LibDock, [15] a relatively fast algorithm 
that conducts 'HotSpots' matching of ligand conformations with 
rigid binding site's HotSpots map that is well-suited for large-
sized libraries, was used to filter the obtained library according 
to their binding capacity into the proposed active site in order 
to decrease the library size. With specified 200 hotspots and 3 
saved for each ligand with conformational sampling using the 
'BEST' algorithm. By the utilization of CDocker [16], the 
protocol that employs a CHARMm-based MD scheme, the 
ligands were docked into receptor binding site, to further 
narrow down the number of top hits on a more precise scale. 
Thus, refining each hit through simulated annealing between 
300 and 700 K. Finally the top ligands were selected for flexible 
docking by using the corresponding protocol in DS 2.5 that 
allows for receptor flexibility [17]. The flexible residues were 
determined to be those of ASP710, SER711, ILE713, ILE724, 
ARG725, ARG726, VAL727, ARG728 and ASP731, which are 
thought to be the critically interactive residues during the 
dimerisation process, and post-docking ChiRotor and ligand-
annealing refinement were allowed.    
   
De Novo design: 
A set of novel ligands were designed by the help of the 'De 
Novo Evolution' protocol, that constructs larger molecules in 
the binding site of the receptor starting from an initial scaffold 
molecule employing a genetic algorithm. The core scaffold was 
manually chosen and further manual modifications were 
carried out on the resulting structures. The protocol was run in 
'Full Evolution' mode starting with a population of 40 at each of 
the 6 generations with the selection of 15 survivors per 
generation using the top LUDI 3 [18] – an empirical function 
that provides a fast and accurate score describing the binding 
affinity – for scoring structures. Designed ligands were first 
heated in the receptor site up to 300 K and trajectories analyzed 
to assure the mode of binding at physiological temperature for 
5 fs with Generalized Born Simple Switching (GBSW) implicit 
solvation conditions – the methodology is well suited with 
molecular dynamics trajectory [19], in order to initially filter the 
candidate structures. 
 
Scoring and Energetics:  
The ligand-receptor complexes of selected clustered poses from 
each flexibly docked ligand, as well as the designed ligands 
were further subject to a minimization process using the 
'Minimization' protocol in DS 2.5 through the 'Smart Minimizer' 
– steepest-descent followed by conjugate gradient method – 
until potential energy RMS gradient was less than 0.05 
kcal/mol/Å, with generalized born simple switching implicit 
solvation at salt concentration of 0.145 M to better mimic 
physiological conditions [20]. The same was done to the 
homodimerised complex for acquiring an energy estimate of the 
low-affinity D7 dimerization. The last followed binding energy 
calculation by the 'Calculate Binding Energy' protocol yet 
through the more robust Poisson-Boltzmann solver. The 
binding energies were used for scoring due to the lack of prior 
arts correlating scoring functions reproducibility on the current 
binding site. 
 
Molecular Dynamics: 
The 'Standard Dynamics Cascade' Protocol [21] of DS 2.5 was 
implemented with a time step of 1 fs. The initial minimization BIOINFORMATION  open access 
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of the implicitly solvated protein–ligand complex was carried 
out in two steps on residues of a selected sphere of a 13 Å 
radius inscribing the ligand, binding site and its surrounding 
residues and loops, keeping about two thirds of the protein 
domain fixed throughout the whole dynamics simulation 
cascade. Bad contacts were corrected using the steepest-descent 
algorithm without major distortion in the structure down to 
0.01 kcal/mol/Å RMS gradient. Further minimization was 
carried out using the conjugate gradient algorithm with a low-
energy starting point down to 0.0001 kcal/mol/Å final RMS 
gradient. Initially the temperature of the system was raised 
from 50 to 330 K for 5000 heating steps at each temperature. The 
system was then equilibrated for 200 ps, and finally the 
production run was carried out for another 1500 ps. 
 
 
Figure 1: Interpolated charge surface of the binding pocket 
residues. 
 
Results and Discussion: 
The detailed investigation conducted by Yang et al.,  [11] 
concluded the critical role of the dimerization process of D7 
through the homotypic contacts in ligand-induced (VEGF-A) 
autophosphorylation of VEGFR-2 and that latter's eventual 
activation. Such interaction was regarded to be of low affinity, 
the fact proven by analytical centrifugation that determined the 
dissociation constant for (Kd) dimerisation of the isolated D7 
region was found to exceed 10-4 M. Relating the total binding 
energy to the dissociation constant, the following formula was 
used: 
 ΔG(lgd-ptn)•ln Kd(ptn-ptn)/ΔG(ptn-ptn) = ln Kd(lgd-ptn)  
Where ΔG is the binding free energy, and Kd is the dissociation 
constant. The reference value was calculated from the molar 
dimerisation free energy of D7 that approximately corresponds 
to a Kd of 100 µM. The above formula was then used to 
calculate dissociation constants of the ligand-protein complexes. 
Eventually, showing potentially efficacious leads resulting from 
the design procedure as opposed to the virtual screening [11]. 
 
Virtual High-throughput Screening: 
The aforementioned selected library of commercially available 
compounds (approximately 110,000 compounds) was initially 
docked with LibDock into the binding pocket (Figure 1) to 
reduce its size down to approximately 35,000 poses – with a 
maximum of three poses per molecule, which was appropriate 
for the more robust CDOCKER protocol, that was allowed to 
perform final annealing, has shrunk down the size into 751 
poses. Based on the 'CDOCKER Energy' score which includes 
internal ligand strain energy and receptor-ligand interaction 
energy, the 19 non-redundant structures of the top 50 poses 
were chosen for an additional flexible docking simulation in 
order to better investigate their mode of binding. The resulting 
complexes output by the latter process were retrospectively 
investigated, and five poses for each ligand-flexible receptor 
poses were selected as candidates for the energetics simulation. 
The purpose of the re-ranking the compounds based on 
thorough energetic probing was to better account solvation and 
entropy-related factors that could strongly affect the binding 
efficacy. So, the complexes were minimized with implicit 
solvation and then the total binding energies (regarding 
receptor and ligand entropy) were calculated to select the best 
ligand. Fifteen out of the nineteen ligands have shown negative 
total binding energies as shown in (Table 1, see Supplementary 
material). The results show a range from very poor to modest 
binding affinities. Hence, FBD is capable of generating more 
robust solutions provided chemical compatibility and synthetic 
feasibility are addressed.  
 
 
Figure 2: The binding modes of the designed compounds 1D-
5D (from left to right). Hydrogen bonds visualized as dashed 
black lines; Cation-pi interactions visualized as orange lines. 
 
De Novo Design of Small Molecule Inhibitors: 
Firstly, we have selected two pharmacophoric groups as 
scaffolds from the designed prototype D3 that have been 
manually placed into the active site and then minimized for the 
Ludi algorithm to start with in 'Full Evolution' mode, namely, 
guanidinium group at the acidic pocket of the active site – by 
natural binding mode mimicry – and tetrazolyl sandwiched 
between the two guanidinium groups of the ARG725 and BIOINFORMATION  open access 
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ARG726. The standard Ludi fragment libraries – 'Link' and 
'Receptor' – developed by Böhm [22]  were used. The 6th 
generation has proved to supply optimally sized candidate 
ligands with sufficiently high LUDI scores. The selected ligands 
were those of the acceptable synthetic feasibility. Later, manual 
optimization for binding enrichment was carried out, mainly 
through replacement of weakly interacting or misplaced 
moieties and addition of electron-rich annular systems in the 
vicinity of the ionisable guanidinium groups of the active site in 
aim to the formation of multiple cation-pi interations, the kind 
of non-covalent bonding that has proved capable of competing 
with full aqueous solvation as well as baring binding energies 
beyond -20 kcal/mol between various protonated amines and 
activated ring systems [23]. Other condition-specific 
interactions were also sought during the design process like 
cyclodione-arginine reversible covalent interaction [24], 
distributed formal and densely charged groups. Preliminary 
heating to 300 K was conducted to discard poorly bound 
ligands, and then the stable complexes were re-cooled to 
decrease the gradient after relieving steric clashes. Then, the 
complexes of the five remaining compounds 1D-5D (Figure 2) 
were minimized and binding energies were calculated (Table 2, 
see Supplementary material). 
 
 
Figure 3: Molecular dynamics trajectory for the complexes of 
the ligands 1D-5D (from left to right). Snapshots of the designed 
ligands and the side chains of the binding site residue 
conformers extracted from the production dynamics trajectory 
at times 0, 250, 500, 750, 1000, 1250, 1500 ps. 
 
Molecular dynamics simulation: 
To account for the effect of solvent on binding stability; GBSW 
implicit solver was used with the same parameters of prior 
minimization. The total energy and simulation temperature 
were found to remain steady with little fluctuation during the 
production stage time interval (1500 ps), which was preceded 
by heating followed by equilibration. The conformational 
sampling of the trajectory at 0, 250, 500, 750, 1000, 1250, and 
1500 ps of the production run are shown in Figure 3. 
Conformations of both the ligand and the protein showed that 
they stayed conserved with slight perturbation, at the solvent 
accessible region by the residues of Arg726 and Arg725, 
especially in the case of the ligands’ 2D rotatable tail. Due to the 
mandatory role played by hydrogen bonds and cation-pi 
interactions, they were closely monitored and their existence 
sampled through the trajectory (Table 3, see Supplementary 
material). From the table it is clear that the bond showed a high 
temporal stability throughout the production dynamics phase. 
Calculating the molecular properties (Table 2, see 
Supplementary material) of the designed ligands could predict 
good pharmacokinetic properties. This should lead to the 
expectation of a valuable in vivo performance of such agents. 
Also in most of the cases, Lipiniski's 'rule of 5' was satisfied, 
which suggests a good oral bioavailability of the compounds 
[25]. Due to the high potentials of these compounds, we are 
planning to synthesize and report their activities in due course.   
 
Conclusion: 
A novel homotypic dimerization region that is believed to play 
a critical role in VEGFR signal transduction was exploited as 
target in structure-based drug design. A large sized library of 
commercially available compounds were virtually screened and 
showed Kd values higher than that of D7 dimerisation. 
Nevertheless, the de novo design process has resulted in many 
promising ligands in the sub-micromolar range (binding 
affinity exceeding 340-fold that of dimerisation). In addition 
designed compounds could be utilized in construction of a 
pharmacophore model to screen much larger databases of 
compounds for possible hits. This study could be a promising in 
developing lead compounds in the discovery of anticancer 
drugs. 
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Supplementary material: 
 
Table 1: Estimated binding energies of the docked ligands.  
L. no.  Zinc  database code  Calculated total binding energy (kcal/mol) 
1 ZINC08743931  -32.73 
2 ZINC15772464  -27.54 
3 ZINC13569749  -23.28 
4 ZINC09176508  -21.18 
5 ZINC05397919  -20.18 
6 ZINC08464180  -17.76 
7 ZINC13465737  -16.19 
8 ZINC17044320  -12.46 
9 ZINC05315206  -12.08 
10 ZINC13638480  -7.53 
11 ZINC13465215  -5.08 
12 ZINC13465217  -3.45 
13 ZINC08772799  -2.44 
14 ZINC18137524  -0.97 
 
Table 2: Binding energies and calculated molecular properties of the newly designed ligands  
L.St. Calculated 
total binding 
energy 
(kcal/mol) 
Predicted 
Kd (µM) 
Molecular 
weight 
Fractional 
polar 
surface area 
AlogP HB 
donors 
HB 
acceptors 
-50.4594 
 
 
 
 
0.2912 
 
 
 
 
 
437.536  0.425  -1.264 6  7 
 
-49.1337 0.4325 
 
 
 
 
 
 
375.475  0.390  -0.567 5  7 
-39.2582 8.2246 
 
 
293.325  0.511  -1.189 3  8 
 
-25.7568 461.1852  487.595  0.332  2.705  4  8 
 
-16.1185 8170.843  404.430  0.353  2.283 5  5 
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Table 3: Amino acid residues making interaction with the designed ligands and stability of theses interactions along the trajectory 
of dynamics simulation 
Time 
(ps) 
H-Bonding and salt-bridging residues  Cation-pi interacting residues 
D1  D2 D3  D4 D5  D1  D2  D3  D4  D5 
0 V708,  D710, 
R726, D731. 
D710, 
R726, 
D731. 
D710, R725, 
R726, D731. 
D710, 
R728, 
D731. 
D710, R726, 
R728, D731. 
R726  R728 R726  R728  R726 
250 D710,  R726, 
D731. 
D710, 
R726, 
D731. 
D710, 
S711, R725, 
R726, D731. 
D710, 
D731. 
D710, R726, 
R728, D731. 
R726 
 
R728 R726 R728 - 
500 D710,  R725, 
R726, D731. 
D710, 
R726, 
D731. 
D710, 
S711, R725, 
R726, D731. 
D710, 
R728, 
D731. 
D710, R725,  
R726, R728, 
D731. 
K702,  
R726 
R728 -  R728 - 
750 D710,  R725, 
R726, D731. 
D710, 
R726, 
D731. 
D710, 
S711, R725, 
R726, D731. 
D710, 
R728, 
D731. 
D710, R726, 
R728, D731. 
K702,  
R726 
R728 R726 R728 R726 
1000 D710,  R725, 
R726, D731. 
D710, 
R726, 
D731. 
D710, 
S711, R725, 
R726, D731. 
D710, 
D731. 
D710, R726, 
R728, D731. 
R726  R728 R725  R728  R726 
1250 D710,  R725, 
R726, D731. 
D710, 
R726, 
D731. 
D710, 
S711, R725, 
R726, R728, 
D731. 
D710, 
R728, 
D731. 
D710, R726, 
R728, D731. 
R726  R728 R726  R728  - 
1500 D710,  R725, 
R726, D731. 
D710, 
R728, 
D731. 
D710, 
S711, R725, 
R726, R728, 
D731. 
D710, 
D731. 
D710, R726, 
R728, D731. 
R726  R728 R726 R728 - 
 
 
 
 
 
 
 